LOW HBV DNA AND HBSAG LEVELS AT 24 WEEKS OFF-TREATMENT PREDICT SUSTAINED RESPONSE AND HBSAG LOSS IN PATIENTS WHO DISCONTINUED ANTIVIRAL THERAPY

Conference Reports for NATAP

The International Liver Congress™
EASL - European Association for the
Study of the Liver
June 21-24 2023


LOW HBV DNA AND HBSAG LEVELS AT 24 WEEKS OFF-TREATMENT PREDICT SUSTAINED RESPONSE AND HBSAG LOSS IN PATIENTS WHO DISCONTINUED ANTIVIRAL THERAPY

	EASL 2023 june 21-24 Vienna